Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Hypoxia-Inducible Factor-1

  • Hyunsuk Shim
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2928-2



Hypoxia is widespread within most solid tumors. This stress situation is sufficient to activate the key transcription factor, hypoxia inducible factor (HIF)-1 that mediates the activation of the survival pathways in cancer cells. HIF-1 can also be induced by oxygen-independent genetic deregulations that activate a variety of oncogene signaling pathways or inactivate tumor suppressors. Increased tumor HIF-1 is often correlated with increased angiogenesis, malignant cancer progression, poor patient prognosis, and resistance to cancer therapies. HIF-1 is a proangiogenic transcription factor that interacts with a specific promoter sequence, called hypoxia response elements (HREs) in the regulatory region of the target DNA to stimulate transcription of multiple angiogenic factors including vascular endothelial growth factor (VEGF). In addition, HIF-1-targeted genes also include genes involved in cell proliferation, survival, invasion, and drug resistance. Due to...


Vascular Endothelial Growth Factor Hypoxia Inducible Factor Vascular Endothelial Growth Factor Production Heat Shock Protein HSP90 Hypoxia Responsive Element 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Hirota K, Semenza GL (2006) Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59(1):15–26CrossRefPubMedGoogle Scholar
  2. Ivan M, Kondo K, Yang H et al (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292(5516):464–468CrossRefPubMedGoogle Scholar
  3. Mabjeesh NJ, Amir S (2007) Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 22(5):559–572PubMedGoogle Scholar
  4. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732CrossRefPubMedGoogle Scholar
  5. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Hematology/OncologyWinship Cancer Institute, Emory UniversityAtlantaUSA